文献速递产科

氨甲环酸预防阴道分娩产后失血:一项双盲随机对照试验

Tranexamic acid in preventing postpartum blood loss in vaginal delivery: a double-blinded randomized controlled trial.
PubMed 文献 · Am J Obstet Gynecol MFM · 2024-08-07

这项双盲随机对照试验纳入650例≥34周单胎阴道分娩孕妇,比较预防性静脉氨甲环酸1 g与安慰剂联合第三产程主动管理对产后失血的影响。结果显示两组平均失血量、原发性产后出血发生率及血红蛋白下降均无显著差异,最常见不良反应为头晕,3个月随访无血栓栓塞事件。

要点

  • 预防性氨甲环酸1 g联合第三产程主动管理未降低阴道分娩后失血量。
  • 两组原发性产后出血发生率无显著差异(15.9% vs 15.3%,P=.814)。
  • 最常见不良反应为头晕,3个月随访两组均无血栓栓塞事件。

核心结论

  • 预防性使用氨甲环酸联合第三产程主动管理对阴道分娩后减少产后失血和产后出血发生率未提供额外获益。

研究设计与样本

  • 双盲随机对照试验,纳入650例≥34周单胎妊娠阴道分娩孕妇,随机接受静脉氨甲环酸1 g或安慰剂联合第三产程主动管理。
  • 使用校准采血袋测量第三产程和第四产程的产后失血量。

主要发现

  • 干预组与安慰剂组平均失血量无显著差异(378.5±261.2 mL vs 383.0±258.9 mL;P=.93)。
  • 原发性产后出血发生率两组相当(A组15.9% vs B组15.3%;P=.814)。
  • 产后12至24小时内血红蛋白定量下降中位数两组相当(A组0.60 g%,四分位距0.40-0.90;B组0.60 g%,四分位距0.40-0.80;P=.95)。
  • 最常见不良反应为头晕,3个月随访两组均无血栓栓塞事件。

关键数值与推荐

  • 预防性氨甲环酸剂量为1 g静脉给药。
  • 产后出血发生率A组15.9% vs B组15.3%(P=.814)。

临床怎么用

  • 原文结论认为预防性氨甲环酸联合第三产程主动管理对阴道分娩后减少产后失血和产后出血发生率未提供额外获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postpartum hemorrhage (PPH) is an obstetrical emergency that occurs in 1% to 10% of all deliveries and contributes to nearly one-quarter of all maternal deaths worldwide. Tranexamic acid has been established as an adjunct in the treatment of PPH but its role in its prevention of PPH following vaginal delivery has not been widely studied. OBJECTIVE: This study aimed to assess the effect of prophylactic tranexamic acid (1 g) along with active management of the third stage of labor in reducing postpartum blood loss and the incidence of postpartum hemorrhage after vaginal delivery. STUDY DESIGN: In this randomized controlled trial, 650 women with singleton pregnancies at ≥34 weeks of gestation who were undergoing vaginal delivery were included. Eligible women were randomly assigned to receive either 1 g of tranexamic acid or placebo intravenously along with active management of the third stage of labor. Calibrated blood collection bags were used to measure postpartum blood loss during the third and fourth stages of labor. RESULTS: Of 886 women approached for the study, 650 who met the inclusion criteria were enrolled, and 320 in group A and 321 in group B were analyzed. The maternal characteristics were similar between the groups. The mean blood loss did not differ significantly between the intervention and placebo groups (378.5±261.2 mL vs 383.0±258.9 mL; P=.93). The incidence of primary postpartum hemorrhage was comparable in both groups (15.9% in group A and 15.3% in group B; P=.814). The median quantitative decreases in hemoglobin levels within 12 to 24 hours after delivery were 0.60 g% (interquartile range, 0.40-0.90) in group A and 0.60 g% (interquartile range, 0.40-0.80) in group B, which were comparable in both groups (P=.95). The most common adverse effect reported was dizziness, and there was no thromboembolic event at 3 months follow-up in either group. CONCLUSION: The use of tranexamic acid as a prophylactic measure along with active management of the third stage of labor does not provide additional benefit in reducing the postpartum blood loss and incidence of postpartum hemorrhage after vaginal delivery. El resumen está disponible en Español al final del artículo.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Arya P, Yadav G, Singh P, et al. Tranexamic acid in preventing postpartum blood loss in vaginal delivery: a double-blinded randomized controlled trial. Am J Obstet Gynecol MFM. 2024. PMID: 39096966. doi:10.1016/j.ajogmf.2024.101450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。